Erik Wiemer

Erik Wiemer is a Researcher at Erasmus MC in the Department of Radiotherapy, where he conducts extensive research in molecular oncology, pharmacology, and cellular mechanisms of disease. His work integrates biochemical, genetic, and pharmacological approaches to understand drug resistance, cell death pathways, and tissue homeostasis.

His primary research interests include:

• Molecular mechanisms of Major Vault Protein (MVP) in disease
• Apoptosis and ferroptosis in cancer cells
• Macrophage polarization and signaling in tissue repair
• Pharmacokinetics and drug response in solid tumors
• Bone metabolism and atherosclerosis
• Ocular and soft tissue malignancies

His recent publications reveal a strong focus on translational research, particularly in desmoid-type fibromatosis, bone loss, and atherosclerotic plaque stability. The studies consistently highlight MVP as a central regulator in cellular stress responses and therapeutic resistance. His work combines in vitro and in vivo models with clinical correlations, emphasizing potential therapeutic targets.

Notable scientific contributions include:

• Elucidating MVP’s role in suppressing bone loss via Fas-mediated apoptosis
• Demonstrating MVP regulation of macrophage polarization in fracture repair
• Revealing sorafenib-induced ferroptosis in fibromatosis enhanced by autophagy inhibition
• Linking MVP to plaque stability through ASK1-JNK suppression
• Identifying microRNA biomarkers for ocular carcinoma differentiation

Dr. Wiemer has supervised 9 research trainees or students, indicating an active role in mentoring the next generation of scientists. His collaborative network spans multiple institutions and disciplines, with strong ties to clinical oncology, immunology, and molecular diagnostics. He is involved in both basic and applied research, with potential implications for drug development and personalized therapy.

He is associated with advanced research infrastructure at Erasmus MC, likely participating in multidisciplinary teams focused on cancer biology, radiotherapy, and regenerative medicine. His lab or research group appears to focus on cellular stress pathways, drug response mechanisms, and molecular diagnostics in oncology.